Published in N Engl J Med on November 19, 1998
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Effect of alpha interferon on the hepatitis C virus replicon. J Virol (2001) 6.18
RNA virus error catastrophe: direct molecular test by using ribavirin. Proc Natl Acad Sci U S A (2001) 5.21
Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev (2000) 3.70
Interference of hepatitis C virus RNA replication by short interfering RNAs. Proc Natl Acad Sci U S A (2003) 2.64
Rate and predictors of treatment prescription for hepatitis C. Gut (2006) 2.31
Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis (2008) 2.19
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans. J Clin Invest (2008) 2.08
Early changes in hepatitis C viral quasispecies during interferon therapy predict the therapeutic outcome. Proc Natl Acad Sci U S A (2002) 2.04
Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report. Gut (2000) 1.94
Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs (2005) 1.93
Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol (2001) 1.92
Eligibility and safety of triple therapy for hepatitis C: lessons learned from the first experience in a real world setting. PLoS One (2013) 1.89
Efficient virus extinction by combinations of a mutagen and antiviral inhibitors. J Virol (2001) 1.86
Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test. J Clin Microbiol (1999) 1.80
Hepatitis C virus genotyping: interrogation of the 5' untranslated region cannot accurately distinguish genotypes 1a and 1b. J Clin Microbiol (2002) 1.78
Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog (2013) 1.75
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro. Antimicrob Agents Chemother (2005) 1.75
Elevated levels of interleukin-8 in serum are associated with hepatitis C virus infection and resistance to interferon therapy. J Virol (2001) 1.74
Clinical guidelines on the management of hepatitis C. Gut (2001) 1.72
Hepatitis C virus subtyping by a core-envelope 1-based reverse transcriptase PCR assay with sequencing and its use in determining subtype distribution among Danish patients. J Clin Microbiol (2003) 1.67
Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials. BMJ (2001) 1.67
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol (2011) 1.59
Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA). J Clin Microbiol (2004) 1.55
Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut (2002) 1.53
Comparative analysis of anti-hepatitis C virus activity and gene expression mediated by alpha, beta, and gamma interferons. J Virol (2002) 1.51
Ribavirin improves early responses to peginterferon through improved interferon signaling. Gastroenterology (2010) 1.43
Activation and evasion of the antiviral 2'-5' oligoadenylate synthetase/ribonuclease L pathway by hepatitis C virus mRNA. RNA (2002) 1.36
Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy. J Virol (2000) 1.32
Perspectives for the treatment of infections with Flaviviridae. Clin Microbiol Rev (2000) 1.30
Antiviral therapy for chronic hepatitis C: past, present, and future. J Gastroenterol (2006) 1.28
Evolution of the hepatitis C virus second envelope protein hypervariable region in chronically infected patients receiving alpha interferon therapy. J Virol (1999) 1.26
Progress on the development of therapeutics against West Nile virus. Antiviral Res (2009) 1.26
Morphine enhances hepatitis C virus (HCV) replicon expression. Am J Pathol (2003) 1.25
Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut (2006) 1.22
Tumor suppressors, chromosomal instability, and hepatitis C virus-associated liver cancer. Annu Rev Pathol (2009) 1.20
Retinopathy in chronic hepatitis C patients during interferon treatment with ribavirin. Br J Ophthalmol (2001) 1.19
Intrahepatic genetic inoculation of hepatitis C virus RNA confers cross-protective immunity. J Virol (2001) 1.17
Virus movements on the plasma membrane support infection and transmission between cells. PLoS Pathog (2009) 1.17
Comparative evaluation of the VERSANT HCV RNA 3.0, QUANTIPLEX HCV RNA 2.0, and COBAS AMPLICOR HCV MONITOR version 2.0 Assays for quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2002) 1.15
Evaluation of the VERSANT HCV RNA 3.0 assay for quantification of hepatitis C virus RNA in serum. J Clin Microbiol (2002) 1.14
Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy. J Virol (2000) 1.14
Strengths and limitations of commercial tests for hepatitis C virus RNA quantification. J Clin Microbiol (2004) 1.12
Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol (2008) 1.11
Peginterferon and ribavirin treatment for hepatitis C virus infection. World J Gastroenterol (2011) 1.10
Injection drug use and the hepatitis C virus: considerations for a targeted treatment approach--the case study of Canada. J Urban Health (2004) 1.10
Chronic viral hepatitis C: management update. CMAJ (2000) 1.10
A multi-step process of viral adaptation to a mutagenic nucleoside analogue by modulation of transition types leads to extinction-escape. PLoS Pathog (2010) 1.08
Effect of ethanol on innate antiviral pathways and HCV replication in human liver cells. Virol J (2005) 1.08
Hepatitis C virus replication is directly inhibited by IFN-alpha in a full-length binary expression system. Proc Natl Acad Sci U S A (2001) 1.07
Inhibition of Borna disease virus replication by ribavirin. J Virol (1999) 1.05
Ribavirin can be mutagenic for arenaviruses. J Virol (2011) 1.03
Design of the PEDS-C trial: pegylated interferon +/- ribavirin for children with chronic hepatitis C viral infection. Clin Trials (2007) 1.03
NMR studies of p7 protein from hepatitis C virus. Eur Biophys J (2009) 1.03
Dendritic cells, regulatory T cells and the pathogenesis of chronic hepatitis C. Virulence (2012) 1.01
Benefit of hepatitis C virus core antigen assay in prediction of therapeutic response to interferon and ribavirin combination therapy. J Clin Microbiol (2005) 1.00
Factors affecting serum concentrations of hepatitis C virus (HCV) RNA in HCV genotype 1-infected patients with chronic hepatitis. J Clin Microbiol (2007) 1.00
Therapeutically targeting RNA viruses via lethal mutagenesis. Future Virol (2008) 0.99
Secondary structure, dynamics, and architecture of the p7 membrane protein from hepatitis C virus by NMR spectroscopy. Biochim Biophys Acta (2010) 0.99
Ribavirin enhances IFN-α signalling and MxA expression: a novel immune modulation mechanism during treatment of HCV. PLoS One (2011) 0.99
Generation and characterization of a hepatitis C virus NS3 protease-dependent bovine viral diarrhea virus. J Virol (2000) 0.99
Suppression of haematopoiesis during therapy of chronic hepatitis C with different interferon alpha mono and combination therapy regimens. Gut (2005) 0.98
Activation and deactivation of a broad-spectrum antiviral drug by a single enzyme: adenosine deaminase catalyzes two consecutive deamination reactions. Antimicrob Agents Chemother (2003) 0.98
L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon-α 2b plus ribavirin. World J Gastroenterol (2011) 0.98
Performance characteristics of the COBAS Amplicor Hepatitis C Virus (HCV) Monitor, Version 2.0, International Unit assay and the National Genetics Institute HCV Superquant assay. J Clin Microbiol (2002) 0.97
Regression of fibrosis in chronic hepatitis C after therapy with interferon and ribavirin. Dig Dis Sci (2003) 0.97
Generation of hepatitis C virus-like particles by use of a recombinant vesicular stomatitis virus vector. J Virol (2002) 0.97
Methamphetamine enhances Hepatitis C virus replication in human hepatocytes. J Viral Hepat (2008) 0.97
Epidemiology and management of infectious diseases in international adoptees. Clin Microbiol Rev (2005) 0.96
Hepatitis C virus genetic variability and evolution. World J Hepatol (2015) 0.96
Inhibition of SARS coronavirus infection in vitro with clinically approved antiviral drugs. Emerg Infect Dis (2004) 0.96
Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother (2003) 0.95
Correlation between pre-treatment quasispecies complexity and treatment outcome in chronic HCV genotype 3a. Virol J (2008) 0.95
The management of chronic viral hepatitis: A Canadian consensus conference 2004. Can J Infect Dis Med Microbiol (2004) 0.95
Mental and physical symptoms associated with lower social support for patients with hepatitis C. World J Gastroenterol (2006) 0.95
Combination of "low-dose" ribavirin and interferon alfa-2a therapy followed by interferon alfa-2a monotherapy in chronic HCV-infected non-responders and relapsers after interferon alfa-2a monotherapy. World J Gastroenterol (2001) 0.94
Liver-specific alpha 2 interferon gene expression results in protection from induced hepatitis. J Virol (2000) 0.94
Reduced expression of Jak-1 and Tyk-2 proteins leads to interferon resistance in hepatitis C virus replicon. Virol J (2007) 0.93
De novo initiation pocket mutations have multiple effects on hepatitis C virus RNA-dependent RNA polymerase activities. J Virol (2004) 0.93
Structurally conserved amino Acid w501 is required for RNA helicase activity but is not essential for DNA helicase activity of hepatitis C virus NS3 protein. J Virol (2003) 0.92
Additive effect of neutralizing antibody and antiviral drug treatment in preventing virus escape and persistence. J Virol (2000) 0.92
The promise of gene therapy in gastrointestinal and liver diseases. Gut (2003) 0.92
Frequency distribution of HCV genotypes among chronic hepatitis C patients of Khyber Pakhtunkhwa. Virol J (2011) 0.92
The ribavirin analog ICN 17261 demonstrates reduced toxicity and antiviral effects with retention of both immunomodulatory activity and reduction of hepatitis-induced serum alanine aminotransferase levels. Antimicrob Agents Chemother (2000) 0.92
Quantification of hepatitis C virus (HCV) in liver specimens and sera from patients with human immunodeficiency virus coinfection by using the Versant HCV RNA 3.0 (branched DNA-based) DNA assay. J Clin Microbiol (2003) 0.92
Molecular biology of liver disorders:the hepatitis C virus and molecular targets for drug development. World J Gastroenterol (2000) 0.91
Collapsing focal segmental glomerulosclerosis with recovery of renal function: an uncommon complication of interferon therapy for hepatitis C. Dig Dis Sci (2001) 0.91
Morphine withdrawal enhances hepatitis C virus replicon expression. Am J Pathol (2005) 0.90
Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol (2013) 0.90
Small interfering RNA targeted to stem-loop II of the 5' untranslated region effectively inhibits expression of six HCV genotypes. Virol J (2006) 0.89
Pegylated interferon α-2b plus ribavirin for older patients with chronic hepatitis C. World J Gastroenterol (2010) 0.89
Bioconjugation of oligonucleotides for treating liver fibrosis. Oligonucleotides (2007) 0.88
Cirrhosis of liver. West J Med (1999) 0.88
Modeling quasispecies and drug resistance in hepatitis C patients treated with a protease inhibitor. Bull Math Biol (2012) 0.88
Hepatitis C-Z: recent advances. Arch Dis Child (2002) 0.88
Combination therapy for hepatitis C infection. N Engl J Med (1998) 0.87
Geographic distribution of hepatitis C virus genotypes in pakistan. Hepat Mon (2014) 0.87
Treatment of hepatitis C virus infection. World J Gastroenterol (2007) 0.87
Nested restriction site-specific PCR to detect and type hepatitis C virus (HCV): a rapid method to distinguish HCV subtype 1b from other genotypes. J Clin Microbiol (2001) 0.87
Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet (2001) 35.17
Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med (1998) 14.40
Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology (2001) 8.09
A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med (1990) 4.53
Proton pump inhibitor treatment is associated with the severity of liver disease and increased mortality in patients with cirrhosis. Aliment Pharmacol Ther (2014) 3.91
Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med (2000) 3.74
Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. J Hepatol (2001) 3.64
Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology (2000) 3.42
The e antigen and vertical transmission of hepatitis B surface antigen. Am J Epidemiol (1977) 3.07
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med (1986) 2.85
Detection of hepatitis B virus DNA in liver and serum: a direct appraisal of the chronic carrier state. Lancet (1981) 2.80
Transjugular intrahepatic portosystemic shunts compared with endoscopic sclerotherapy for the prevention of recurrent variceal hemorrhage. A randomized, controlled trial. Ann Intern Med (1997) 2.69
Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature (1990) 2.61
Primary structure and transcription of the genes coding for the two virion phosphoproteins pp65 and pp71 of human cytomegalovirus. J Virol (1987) 2.60
Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet (2000) 2.58
Effect of microaerophilic cell growth conditions on expression of the aerobic (cyoABCDE and cydAB) and anaerobic (narGHJI, frdABCD, and dmsABC) respiratory pathway genes in Escherichia coli. J Bacteriol (1996) 2.54
Endoscopic transhiatal drainage of a mediastinal pancreatic pseudocyst. Endoscopy (2004) 2.34
Cyclosporin A treatment in primary biliary cirrhosis: results of a long-term placebo controlled trial. Gastroenterology (1993) 2.32
Right lobe living donor liver transplantation. Transplantation (1999) 2.31
Influence of delta infection on severity of hepatitis B. Lancet (1982) 2.31
Performance of Acoustic Radiation Force Impulse imaging for the staging of liver fibrosis: a pooled meta-analysis. J Viral Hepat (2011) 2.30
Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection. Aliment Pharmacol Ther (2014) 2.22
Mumps arthritis: unusual presentation as adult Still's disease. Ann Intern Med (1982) 2.21
Waterborne outbreak of intestinal microsporidiosis in persons with and without human immunodeficiency virus infection. J Infect Dis (1999) 2.20
Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther (2014) 2.19
Severe 25-hydroxyvitamin D deficiency identifies a poor prognosis in patients with hepatocellular carcinoma - a prospective cohort study. Aliment Pharmacol Ther (2014) 2.18
Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg (1997) 2.16
A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med (1995) 2.06
Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology (2000) 1.97
Sepsis in cirrhosis: report on the 7th meeting of the International Ascites Club. Gut (2005) 1.93
Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature. J Viral Hepat (2001) 1.89
Symptomatic relapse of neurologic syphilis after benzathine penicillin G therapy for primary or secondary syphilis in HIV-infected patients. Clin Infect Dis (2006) 1.77
[Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol (2010) 1.76
Pilot study of the combination of interferon alfa and ribavirin as therapy of recurrent hepatitis C after liver transplantation. Hepatology (1997) 1.74
Randomized, controlled trial of recombinant human alpha-interferon in patients with chronic hepatitis B. Gastroenterology (1988) 1.74
The natural history of portal hypertension after transjugular intrahepatic portosystemic shunts. Gastroenterology (1997) 1.74
Validity and reliability of the Italian version of the Chronic Liver Disease Questionnaire (CLDQ-I) for the assessment of health-related quality of life. Dig Liver Dis (2005) 1.69
Complications of transjugular intrahepatic portosystemic shunt: a comprehensive review. Radiographics (1993) 1.68
Acquired protein S deficiency: correlation with advanced disease in HIV-1-infected patients. J Acquir Immune Defic Syndr (1992) 1.67
Serological pattern "anti-HBc alone": report on a workshop. J Med Virol (2000) 1.65
Changing of hepatitis C virus genotype patterns in France at the beginning of the third millenium: The GEMHEP GenoCII Study. J Viral Hepat (2005) 1.64
Detection of residual hepatitis C virus RNA by transcription-mediated amplification in patients with complete virologic response according to polymerase chain reaction-based assays. Hepatology (2000) 1.64
Common dysregulation of Wnt/Frizzled receptor elements in human hepatocellular carcinoma. Br J Cancer (2008) 1.59
Cost-effectiveness of 24 or 48 weeks of interferon alpha-2b alone or with ribavirin as initial treatment of chronic hepatitis C. International Hepatitis Interventional Therapy Group. Am J Gastroenterol (2000) 1.57
Selection and outcome of living donors for adult to adult right lobe transplantation. Transplantation (2000) 1.57
An economic evaluation of Herceptin in adjuvant setting: the Breast Cancer International Research Group 006 trial. Ann Oncol (2005) 1.56
The hematologic consequences of transjugular intrahepatic portosystemic shunts. Hepatology (1996) 1.55
Hepatitis C virus replication in 'autoimmune' chronic hepatitis. J Hepatol (1991) 1.52
Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol (1999) 1.51
Randomized controlled trial of adenine arabinoside 5'-monophosphate in chronic active hepatitis B: comparison of the efficacy in heterosexual and homosexual patients. Hepatology (1989) 1.50
Differentiation between benign and malignant adrenal mass using contrast-enhanced ultrasound. Ultraschall Med (2011) 1.50
Strong constraints on the rare decays B(s)(0) → μ+ μ- and B0 → μ+ μ-. Phys Rev Lett (2012) 1.50
First observation of the decays B(0) → D(+)K(-)π(+)π(-) and B(-) → D(0)K(-)π(+)π(-). Phys Rev Lett (2012) 1.50
[Combination of Sabal and Urtica extract vs. finasteride in benign prostatic hyperplasia (Aiken stages I to II). Comparison of therapeutic effectiveness in a one year double-blind study]. Urologe A (1997) 1.46
Decline in pulmonary function during chronic hepatitis C virus therapy with modified interferon alfa and ribavirin. J Viral Hepat (2013) 1.46
Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl (2001) 1.45
The HBV HBX gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J (1985) 1.45
A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther (2004) 1.45
IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C. J Hepatol (2011) 1.45
Transcription-mediated amplification is more sensitive than conventional PCR-based assays for detecting residual serum HCV RNA at end of treatment. Am J Gastroenterol (2001) 1.44
Randomised, double-blind, placebo-controlled trial of ditiocarb sodium ('Imuthiol') in human immunodeficiency virus infection. Lancet (1988) 1.43
Side effects of corticosteroid therapy. Psychiatric aspects. Arch Gen Psychiatry (1981) 1.43
Prevalence of hepatitis G virus and its strain variant, the GB agent, in blood donations and their transmission to recipients. Transfusion (1997) 1.42
Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42
Liver regeneration and function in donor and recipient after right lobe adult to adult living donor liver transplantation. Transplantation (2000) 1.42
Dynamics of hepatitis B virus quasispecies heterogeneity and virologic response in patients receiving low-to-moderate genetic barrier nucleoside analogs. J Viral Hepat (2012) 1.42
Assessment, by transcription-mediated amplification, of virologic response in patients with chronic hepatitis C virus treated with peginterferon alpha-2a. J Clin Microbiol (2001) 1.42
A flow cytometric method to detect anti-pyruvate dehydrogenase antibody in primary biliary cirrhosis. Am J Clin Pathol (1992) 1.39
Comparative histologic features of liver biopsy specimens from patients coinfected with hepatitis G and C viruses with chronic hepatitis C virus alone: an age-, sex-, disease duration-, and transmission-matched controlled study of chronic hepatitis. Am J Clin Pathol (1997) 1.38
Treatment of chronic hepatitis C with interferon alfa-n3: a multicenter, randomized, open-label trial. Hepatology (1997) 1.38
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis. Aliment Pharmacol Ther (2008) 1.36
Review article: specifically targeted anti-viral therapy for hepatitis C - a new era in therapy. Aliment Pharmacol Ther (2010) 1.36
Portosystemic encephalopathy after transjugular intrahepatic portosystemic shunt: results of a prospective controlled study. Hepatology (1994) 1.35
Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis. N Engl J Med (1981) 1.34
Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med (1987) 1.33
A multicenter, placebo-controlled, randomized, double-blind, prospective trial of prophylactic ursodiol for the prevention of gallstone formation following gastric-bypass-induced rapid weight loss. Am J Surg (1995) 1.33
Treatment of chronic hepatitis C in active drug users. N Engl J Med (2001) 1.32
Resolution of a contraceptive-steroid-induced hepatic adenoma with subsequent evolution into hepatocellular carcinoma. Ann Intern Med (1986) 1.31
Immunoreactive elastase I: clinical evaluation of a new noninvasive test of pancreatic function. Clin Chem (1996) 1.31
Role of immune complexes involving SH antigen in pathogenesis of chronic active hepatitis and polyarteritis nodosa. Lancet (1971) 1.30
Multicenter performance evaluation of a new TaqMan PCR assay for monitoring human immunodeficiency virus RNA load. J Clin Microbiol (2006) 1.29
Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology (1999) 1.29
Transjugular intrahepatic portosystemic shunts for patients with active variceal hemorrhage unresponsive to sclerotherapy. Gastroenterology (1996) 1.28
Tattoo application is not associated with an increased risk for chronic viral hepatitis. Am J Gastroenterol (2000) 1.28